By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel generally agrees that the Schedule III rescheduling provides limited immediate benefits to Canopy Growth (CGC) due to its non-controlling interest in Canopy USA. However, there's disagreement on the long-term implications. Some panelists see potential for a sector re-rating and institutional capital inflow, while others argue that CGC's minority position leaves it vulnerable to dilution and competition from U.S. MSOs with controlling stakes.
Risk: CGC's minority exposure in Canopy USA could lead to dilution and loss of governance rights, making it vulnerable to competition from U.S. MSOs with controlling stakes.
Opportunity: A sector-wide re-rating triggered by Schedule III could provide significant long-term benefits to CGC through its equity-linked warrants in Canopy USA, acting as a levered derivative on U.S. market access.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Medical marijuana was moved to the DEA's Schedule III from Schedule I.
This confers some accounting advantages, at best, and the company can't even capitalize on them yet.
A long-awaited change in U.S. federal marijuana law occurred in late April, when the Drug Enforcement Administation rescheduled marijuana from its high-risk Schedule I to a Schedule III designation, which is for drugs with accepted medical use and low potential for dependence. The move was initially seen as a historic change for the drug and the industry that's grown up around it.
However, the impact thus far has been relatively muted. Nevertheless, the reform will make a difference to certain cannabis companies. Let's look at how it might -- or, more appropriately, might not -- affect one of Canada's top marijuana companies, Canopy Growth (NASDAQ: CGC).
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The very large catch in the DEA's rescheduling of cannabis is that it applies solely to medical marijuana, not the recreational variety. And medical is restricted, logically enough, to users deemed to have at least one affliction that the drug can treat.
Nevertheless, for some purveyors of pot destined for healthcare use, this is going to make a difference both operationally and financially.
The most crucial of these changes, arguably, is that, in the shift from Schedule I to III, medical product sales are no longer subject to Internal Revenue Service Section 280E. That means companies selling them are no longer limited to deducting only their cost of goods sold; they can also deduct standard business expenses (marketing/advertising, rent, salaries, insurance, and so on).
While this might not exactly result in a windfall for cannabis companies, it provides plenty of relief for those involved in the medical segment. But again, there's a catch here -- Health Canada, that country's healthcare regulator, narrowly limits cannabis export permits to certain medical or research uses. Therefore, north-of-the-border cannabis companies don't have an easy channel to the U.S. for medical products.
Canopy Growth, of course, is a presence on the U.S. market anyway, albeit at some distance. It has an affiliate, Canopy USA, in which it holds only a non-controlling interest, to maintain its clutch of American assets (including medical pot businesses). Of course, there's a catch: The parent company cannot consolidate Canopy USA's results into its own.
So ultimately, we don't have a good fix on how much medical weed Canopy's U.S. "affiliate" sells. Also, absent more meaningful legal reform, this situation won't change, and these sales will remain unconsolidated.
It's likely that this situation is a major reason Canopy Growth officials haven't broken out the party hats. The change will directly affect it when, or if, it graduates to a controlling interest in Canopy USA. Only then can the unit's results be incorporated into its own.
So what are we left with here? Canopy Growth is one of Canada's top pot companies, but given the industry's many struggles, that's not an enviable position. Net profits have been very far and few between, and net losses have been considerable at times. The company's free cash flow habitually runs negative as well.
A clutch of acquisitions hasn't helped lift it into the black; meanwhile, frequent (and often substantial) secondary share issues have left early investors much diluted and, surely, more than a little disappointed.
Legalization in the U.S., or at least a fuller rescheduling of marijuana, is the pearl that many a Canadian pot company with an eye on this country clutches to.
However, I'm not convinced this will be a magic success maker for any weed business, least of all Canopy Growth; the U.S. market is already competitive, and those Canopy USA units aren't collectively powerful enough to dominate what's still a fragmented industry.
The Great Marijuana Rescheduling of 2026, which in the end wasn't so great, isn't going to affect Canopy Growth in any material way. At least, not soon. And given how the company continues to perform, I don't think its stock is a buy.
Before you buy stock in Canopy Growth, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Canopy Growth wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $463,900! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,401!
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 2, 2026. *
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Schedule III is a floor, not a ceiling—the real upside lies in whether it catalyzes FDA engagement and full descheduling within 2–3 years, which the article dismisses but shouldn't."
The article conflates two separate problems: (1) Schedule III's actual benefit—Section 280E relief for medical cannabis—is real but narrow, and (2) Canopy's structural inability to capture it due to non-controlling interest in Canopy USA. The author is correct that this doesn't move the needle for CGC near-term. However, the piece undersells a critical second-order effect: if Schedule III legitimizes medical cannabis supply chains, it could trigger FDA pathway clarity within 24–36 months, which would unlock full federal rescheduling or descheduling. That's the real catalyst, not the 280E deduction. CGC's valuation already reflects despair; a credible FDA timeline could re-rate the entire sector 40–60% before fundamentals improve.
The article may be right that even full U.S. legalization won't save CGC—the company has chronic cash burn, massive dilution, and no competitive moat. A legal win doesn't fix operational incompetence, and the U.S. market is already crowded with better-capitalized players.
"Canopy Growth's non-consolidated U.S. exposure and persistent losses mean the rescheduling change will not improve its financial trajectory in the foreseeable future."
The article correctly identifies that Schedule III status mainly eases 280E tax burdens for medical cannabis, yet Canopy Growth cannot consolidate Canopy USA results due to its non-controlling interest. This structural barrier, combined with Health Canada's export limits, means the rescheduling delivers negligible operational or financial upside. Canopy's history of negative free cash flow, repeated dilutions, and inability to achieve consistent profitability further weakens any bullish thesis. Investors should focus on full U.S. legalization timelines rather than incremental federal tweaks that bypass Canadian operators.
A controlling stake in Canopy USA could be acquired faster than modeled, or broader banking and tax reforms could follow rescheduling and lift the entire sector including CGC regardless of its current structure.
"Rescheduling is a long-term institutional legitimacy catalyst rather than an immediate accounting windfall for Canadian LPs."
The article correctly identifies the immediate 280E tax relief as a non-event for Canopy Growth (CGC) due to its unconsolidated structure, but it misses the forest for the trees regarding the regulatory signaling. Schedule III is a massive, irreversible shift in the federal posture toward cannabis. While CGC is currently a cash-burning machine with a history of dilution, the rescheduling provides a runway for institutional capital to enter the space, potentially lowering their cost of capital for future M&A. This is less about immediate P&L impact and more about the long-term legitimization of the U.S. asset base they have meticulously positioned through Canopy USA. CGC remains a high-beta play on federal normalization, not a fundamental value pick.
The strongest bear case is that Schedule III does nothing to address the interstate commerce ban, meaning the U.S. market remains a fragmented collection of state-level silos where Canopy’s scale advantages are structurally nullified.
"The rescheduling only translates into meaningful upside for CGC if Canopy USA becomes a controlling, consolidated unit; otherwise the benefits from 280E relief are largely unrealized."
Rescheduling is a nuanced win. For CGC, the immediate tax relief from 280E is real but contingent on Canopy USA becoming a controlling, consolidated unit. Today, Canopy Growth only holds a non-controlling stake, so any U.S. medical sales and associated margins flow through as unconsolidated lines at best. Beyond that, the federal legality gap, state-by-state restrictions, and competitive U.S. MSOs keep true profitability a long way off. The stock would need a near-term trigger—either a path to control of Canopy USA or a clear U.S. expansion plan with cost structure improvements—for a meaningful multiple re-rating. In other words, optionality, not a cure.
Still, bulls might argue optionality could materialize sooner than expected if Canopy USA moves toward consolidation or if broader U.S. reform accelerates. In that case, the stock could re-rate despite current profitability concerns.
"Schedule III's banking + enforcement relief helps U.S. operators scale, but whether CGC's minority stake captures upside depends on competitive positioning, not just capital availability."
Gemini flags the interstate commerce ban as a structural nullifier—correct, but incomplete. Schedule III doesn't solve that directly. However, it *does* enable federal banking access and removes DEA enforcement risk, which lets state-level operators scale within their borders without federal prosecution. That's not nothing. The real question: does lower cost of capital for U.S. MSOs (via banking + institutional flows) benefit CGC's non-controlling Canopy USA stake, or does it just strengthen competitors? Nobody's modeled that spread.
"Banking access strengthens controlling MSOs and widens CGC's structural disadvantage via its non-controlling stake."
Claude assumes federal banking access flows through to benefit Canopy USA's non-controlling stake, yet MSOs with direct control will capture cheaper capital first and accelerate consolidation. CGC's minority position leaves it exposed to dilution without governance rights, turning banking reform into a competitive disadvantage rather than a tailwind. The spread between controlling and non-controlling economics widens, not narrows, post-rescheduling.
"CGC's non-controlling interest functions as a levered derivative on U.S. market access, making it a high-risk play on sector re-rating rather than a fundamental value proposition."
Grok correctly identifies the capital disadvantage for CGC, but both Grok and Claude ignore the 'option value' of the Canopy USA structure. If Schedule III triggers a sector-wide re-rating, CGC’s equity-linked warrants in Canopy USA act as a levered derivative on U.S. market access. The risk isn't just dilution; it's that CGC is a 'wasting asset' if they cannot convert those interests before the U.S. MSOs achieve total market dominance and pricing power.
"CGC's optionality via Canopy USA warrants is not a reliable path to upside; sector re-rating alone won't overcome dilution and control dynamics."
Responding to Gemini: the 'option value' of Canopy USA warrants is real but fragile. A sector re-rating depends on timely federal normalization, not CGC’s pace. MSOs with controlling stakes will capture cheaper capital and pricing power first, leaving CGC’s minority exposure vulnerable to dilution. Warrants could be illiquid or significantly out-of-the-money for years, and the conversion trigger is uncertain. In short, optionality exists, but the upside is far from a one-way bet.
The panel generally agrees that the Schedule III rescheduling provides limited immediate benefits to Canopy Growth (CGC) due to its non-controlling interest in Canopy USA. However, there's disagreement on the long-term implications. Some panelists see potential for a sector re-rating and institutional capital inflow, while others argue that CGC's minority position leaves it vulnerable to dilution and competition from U.S. MSOs with controlling stakes.
A sector-wide re-rating triggered by Schedule III could provide significant long-term benefits to CGC through its equity-linked warrants in Canopy USA, acting as a levered derivative on U.S. market access.
CGC's minority exposure in Canopy USA could lead to dilution and loss of governance rights, making it vulnerable to competition from U.S. MSOs with controlling stakes.